Claris Lifesciences Limited IPO Message Board (Page 25)

So many IPO/FPO ,limited money ,at aloss what to do

now this is 6 times bigger when compared to RPP in terms of Issue Size..what does our experts advice in terms of
1) this specific IPO
2) so many IPO/FPO at same time

Claris Lifesciences IPO


Carlyle-backed Claris Lifesciences is looking to raise over Rs 300 crore through its maiden public float. As per VCCircle estimates, Carlyle could be sitting on as much as 3x unrealised gains on its four-year-old investment in the Ahmedabad-based drugmaker.Carlye through First Carlyle Ventures III had invested $20 million (~Rs 90 crore) in Claris Lifesciences in March 2006, through preferential shares that represents 13.89% stake currently. Its average cost iof purchase works out to be around Rs 127 a piece.Claris is yet to declare how much equity it plans to dilute in the IPO, but assuming the promoters would like to maintain 75% stake in the company after the issue (the maximum allowed as against their current holding of 86%), it could mean about 15% dilution in equity base through fresh issue of around 7.3 million shares. This could translate into an issue price of around Rs 410 a share, over three times the cost price for Carlyle.Claris plans to use IPO funds to set up some new manufacturing lines besides repayment of Rs 50-crore term loan.Carlyle’s investment was to fund expansion in capacity, establishing new facilities, R&D and product development initiatives. The 10-year-old firm’s product basket includes the high-end critical care segments such as clinical nutrition, anesthesia, blood products, plasma expanders, transplant, dialysis, anti-infectives, and cardiology.For the year ended December’09, Claris had net revenue of Rs 621 crore with net profit of Rs 125 crore. With 15% equity dilution, the company could be looking at an EPS of around Rs 21 on its FY’09 earnings post issue translating into a P/E multiple of around 20 if the issue price is close to Rs 410. This would give it a market cap of around Rs 2,395 crore or $540 million.Some of the other current investments of Carlyle in India include HDFC, Great Offshore and Allsec Technologies.
Claris Lifesciences IPO – VCCIRCLE
Details about Claris Lifesciences IPO from VCCIRCLE
Carlyle-backed Claris Lifesciences is looking to raise over Rs 300 crore through its maiden public float. As per VCCircle estimates, Carlyle could be sitting on as much as 3x unrealised gains on its four-year-old investment in the Ahmedabad-based drugmaker.
Carlye through First Carlyle Ventures III had invested $20 million (~Rs 90 crore) in Claris Lifesciences in March 2006, through preferential shares that represents 13.89% stake currently. Its average cost iof purchase works out to be around Rs 127 a piece.
Claris is yet to declare how much equity it plans to dilute in the IPO, but assuming the promoters would like to maintain 75% stake in the company after the issue (the maximum allowed as against their current holding of 86%), it could mean about 15% dilution in equity base through fresh issue of around 7.3 million shares. This could translate into an issue price of around Rs 410 a share, over three times the cost price for Carlyle.
Claris plans to use IPO funds to set up some new manufacturing lines besides repayment of Rs 50-crore term loan.
Carlyle’s investment was to fund expansion in capacity, establishing new facilities, R&D and product development initiatives. The 10-year-old firm’s product basket includes the high-end critical care segments such as clinical nutrition, anesthesia, blood products, plasma expanders, transplant, dialysis, anti-infectives, and cardiology.
For the year ended December’09, Claris had net revenue of Rs 621 crore with net profit of Rs 125 crore. With 15% equity dilution, the company could be looking at an EPS of around Rs 21 on its FY’09 earnings post issue translating into a P/E multiple of around 20 if the issue price is close to Rs 410. This would give it a market cap of around Rs 2,395 crore or $540 million.
Some of the other current investments of Carlyle in India include HDFC, Great Offshore and Allsec Technologies.

opinion contributors to this IPO seem to have just started .some information on the following points are necessary when investing -
i)IPO rating,ii)post issue equity/holding of promoters iii)P/E this fiscal and comparison with the industry average P/E iv)the promoters seem to be people with commerce background ,hence the people heading their manufacturing ,R&D, their experience are important for sustainable growth.So far, they seem to have done well.Price band should be watched.

this company belongs to handa family of ahmedabad who were earlier the promoters of CORE PARENTERALS LTD....core came out with its ipo in 1992 @195/-per share....after listing gave 1:1 bonus for two consecutive years and share was qouted at rs.450 plus....after that due to huge expansion and price war in iv fluids market the company collapsed and became bankrupt.....investors who remain invested in the company got nothing but promoters started new venture in the name of claris

hi friends, I have made DMR (Daily Market Research) on recent IPOs viz., tecpro and coalindia. For Tecpro the upper price band is Rs.410 and lower price band is Rs.380/- For coalindia it is Rs.340-Rs.320. If you own scrips sell at upper band and wait for one or two days for scrip to hit the lower price band and buy. I have made sizeable profits by this way and still have scrips with me.

The initial public opening (IPO) of Claris Lifesciences, a sterile injectables pharmaceutical company, is set to enter capital market for subscription on November 24 and close on November 26, 2010.
The company aims to raise Rs 300 crore through IPO.

As per the draft prospectus, Claris is one of the largest Indian sterile injectables pharmaceutical companies with a presence in 76 countries worldwide. Products offering comprises 113 products across multiple markets and therapeutic areas. All of its products are off-patent products, a significant majority of which are capable of being directly injected into the body and are predominantly used in the treatment of critical illnesses.
Proceeds of the issue will be used for setting up of a new plant comprising a small volume parenterals line - a PVC bag line, a non-PVC bag line and a fat emulsion line. It will be used for setting up of a new manufacturing line for propofol and other fat emulsion products at existing plant in Clarion IV. The funds will also be used construction of a facility for research and development at Clarion manufacturing facilities; and prepayment of an identified term loan.
Enam Securities Private Limited, Edelweiss Capital Limited, JM Financial Consultants Private Limited and ICICI Securities Limited are the book running lead managers to the issue.

1.      Who are the Book Running Lead Managers (BRLM) to the issue?
a.      Enam Securities Private Limited
b.      Edelweiss Capital Limited
c.      JM Financial Consultants Private Limited
d.       ICICI Securities Limited
2.      Which Exchange will the stock be listed on?
The stock is proposed to be listed on the Bombay Stock Exchange (BSE: www.bseindia.com)
3.      When does the Claris Financial Year end?
The Claris Financial year ending is on the 31st of December
4.      What is the Total Income and Profits of Claris for the last 12 months?
The total Income for the year ending 31st December 2009 was Rs. 7,594.01 million and the net profit after taxation for the year ending 31st December 2009 stood at Rs. 1,248.92 million.
5.      What does Claris plan to do with the proceeds of the IPO?
We intend to utilize the Issue Proceeds primarily for the following objects:
a.       Setting up of a new plant comprising a small volume parenterals line, a PVC bag line, a non-PVC bag line and a fat emulsion line.
b.       Setting up of a new manufacturing line for Propofol and other fat emulsion products at our existing plant, Clarion IV.
c.       Construction of a facility for research and development at our Clarion manufacturing facilities.
d.       Prepayment of an identified term loan.
Top
6.      Does the Claris production facility have approvals from any Important Regulatory Authorities?
Our manufacturing facilities are located in Ahmedabad, India. Certain of these facilities have been approved by foreign regulatory authorities including the USFDA, MHRA (UK), TGA (Australia), NAM (Finland), GCC FDCA (Gulf Cooperation Council, including Saudi Arabia, U.A.E. and other countries in the Middle East) and INVIMA (Colombia).
Our manufacturing facilities are ISO 9001-2000 and WHO GMP certified.
7.      Has Claris won any significant awards for it’s Manufacturing Facilities?
The Company has won the Indian Drug Manufacturer Association’s Quality Excellence Award in 2007 and 2008 and the Frost & Sullivan India Manufacturing Excellence Award in 2007, 2008 and 2009 in recognition of the quality of its practices.
8.      What is the staff strength of the Claris?
As of March 31, 2010, we had around 1,553 employees worldwide, of which around 1,486 employees were in India. We employed around 67 nationals in the company. The average age of our senior management team members is approximately 40 years and the average age of our employees is approximately 29 years. The number of man days invested in training was of over 5,000 days during the financial year ended December 31, 2009.
9.      Is ASBA facility available during the IPO?
Bidders may participate in this Issue through ASBA by providing the details of their respective bank accounts
10.      Who are the bankers to Claris?
Allahabad Bank
S.P. Nagar Branch, Behind Sardar Patel Seva Samaj Bhavan C.G. Road, Ahmedabad – 380 006
Andhra Bank
41, Parimal Society, Ellisbridge, C.G. Road, Ahmedabad – 380 006
Barclays Bank PLC
801/808 Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018
Canara Bank
Bhadra Branch, Opposite Advance Complex Bhadra, Ahmedabad – 380 001
Central Bank of India
Gulbai Tekra Branch, Sears Tower, Gulbai Tekra, Ahmedabad – 380 006
HDFC Bank Ltd.
304, 3rd floor Prerna Arcade, Near Parimal Garden, C.G. Road, Ahmedabad – 380 006
Indian Overseas Bank
C.G. Road Branch, Mardia Plaza Complex Nr. Associated Petrol Pump, C.G. Road, Ahmedabad – 380 006
Punjab National Bank
Large Corporate Branch, A wing, Pelican Building, Ashram Road, Ahmedabad – 380009
The Lakshmi Vilas Bank Limited
1st floor, Blue Star Complex, Nr. Old High Court, Railway Crossing, Navrangpura,Ahmedabad – 380 014
United Bank of India
United Bank of India Building, Lal Darwaja, Ahmedabad – 380 001
Top
11.      Who is the Statutory Auditor of Claris?
Deloitte, Haskins & Sells are the statutory auditors of the company.
12.      How many Product Registrations does Claris hold?
As of March 31, 2010, we had obtained over 1,000 registrations worldwide and approximately 410 applications were pending approval.
13.      Where is the Claris Office located?
The Company’s registered and corporate office is situated at:
Claris Corporate Headquarters,
Near Parimal Railway Crossing,
Ellisbridge, Ahmedabad – 380 006, India
Tel: +91 79 26563331
Fax: +91 79 26565879
Website: www.clarislifesciences.com
Email: ipo.corp@clarislifesciences.com
14.      Who is the registrar to the issue?
LINK INTIME INDIA PRIVATE LIMITED is the Registrar to the Issue.

an ahmedabad based pharma company. will give good returns.